# Role of laser therapy in enhancing chemotherapy efficiency in breast cancer: low level laser therapy, photochemotherapy, and photodynamic therapy as promising treatments

**Authors:** Aya E. Mohamed, Wafaa R. Mohamed, Mai A. Elhemely, Tarek Mohamed

PMC · DOI: 10.1007/s10103-025-04771-7 · Lasers in Medical Science · 2026-02-24

## TL;DR

This paper reviews how laser therapies like LLLT, photochemotherapy, and PDT can improve chemotherapy effectiveness in treating breast cancer.

## Contribution

The paper systematically reviews laser-based therapies as adjuncts to chemotherapy, emphasizing their potential to enhance treatment precision and efficacy.

## Key findings

- Laser therapies can modulate the tumor microenvironment and improve drug delivery.
- Photodynamic Therapy (PDT) shows localized cytotoxic effects while sparing healthy tissues.
- Variability in laser parameters remains a barrier to clinical adoption.

## Abstract

Breast cancer is one of the most prevalent and biologically diverse malignancies in women worldwide, encompassing subtypes such as ductal carcinoma in situ (DCIS), lobular carcinoma, and triple-negative breast cancer (TNBC). These variants present complex therapeutic challenges. Chemotherapy remains a core treatment modality, particularly in aggressive or advanced stages, yet its systemic toxicity and lack of specificity limit its efficacy. In recent years, laser-based therapies have emerged as adjunctive strategies to enhance therapeutic precision. This review explores breast cancer classification, progression, and treatment, with an emphasis on chemotherapy, and critically examines the emerging role of laser technologies, including low-level laser therapy (LLLT), Photochemotherapy, and Photodynamic Therapy (PDT), as adjunctive or alternative therapeutic options. We highlight the potential of laser to modulate the tumor microenvironment, improve drug delivery, regulate mitochondrial function, and enhance apoptosis. PDT showed promise in activating localized cytotoxic effects while sparing surrounding tissues. However, heterogeneity in laser parameters and treatment protocols remains a significant barrier to clinical translation. This review underscores the translational potential of laser-assisted chemotherapy, identifies current gaps, and suggests future research directions for optimized treatment strategies in breast oncology.

Breast cancer subtypes pose significant diagnostic and therapeutic challenges.

Laser-based therapies are emerging as promising strategies in breast cancer treatment.

Photobiomodulation modulates tumor microenvironment and promotes tissue regeneration.

Photochemotherapy involves light interaction with chemotherapy, improving antitumor effect.

Photodynamic Therapy involves photosensitizer activation by laser to generate ROS.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989), ductal carcinoma in situ (DCIS) (MONDO:0005023), lobular carcinoma (MONDO:0000552)

## Full-text entities

- **Genes:** PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, TOP2A (DNA topoisomerase II alpha) [NCBI Gene 7153] {aka TOP2, TOP2alpha, TOPIIA, TP2A}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, APAF1 (apoptotic peptidase activating factor 1) [NCBI Gene 317] {aka APAF-1, CED4}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, CAT (catalase) [NCBI Gene 847], NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, RYR1 (ryanodine receptor 1) [NCBI Gene 6261] {aka CCO, CMYO1A, CMYO1B, CMYP1A, CMYP1B, KDS}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, CHEK2 (checkpoint kinase 2) [NCBI Gene 11200] {aka CDS1, CHK2, HuCds1, LFS2, PP1425, RAD53}, BARD1 (BRCA1 associated RING domain 1) [NCBI Gene 580], TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, RAD51C (RAD51 paralog C) [NCBI Gene 5889] {aka BROVCA3, FANCO, R51H3, RAD51L2}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}
- **Diseases:** Phyllodes tumors (MESH:D003557), chronic infections (MESH:D000088562), IBC (MESH:D058922), inflammation (MESH:D007249), metastasis (MESH:D009362), scurvy (MESH:D012614), LCIS (MESH:D000071960), hematological toxicities (MESH:D006402), pain (MESH:D010146), neonatal jaundice (MESH:D007567), deaths (MESH:D003643), eczema (MESH:D004485), breast lesions (MESH:D061325), colorectal, prostate, and stomach cancers (MESH:D015179), mitochondrial dysfunction (MESH:D028361), skin disorders (MESH:D012871), carcinogenic chemicals (MESH:D019966), Paget's disease of the breast (MESH:D010144), infection (MESH:D007239), lung cancer (MESH:D008175), neurotoxicity (MESH:D020258), DCIS (MESH:D002285), Luminal B cancers (MESH:D009369), ototoxicity (MESH:D006311), vitiligo (MESH:D014820), cytotoxic (MESH:D064420), ILC (MESH:D018275), hepatitis B and C (MESH:D006509), rheumatism (MESH:D012216), swelling (MESH:D004487), IDC (MESH:D044584), lymphomas (MESH:D008223), phototoxicity (MESH:D017484), alopecia (MESH:D000505), nausea (MESH:D009325), breast cancer (MESH:D001943), obesity (MESH:D009765), TNBC (MESH:D064726), Paget's disease (MESH:C537701), heart damage (MESH:D006331), breast, ovarian, prostate, lung, and (MESH:D010051), tuberculosis (MESH:D014376), cardiac toxicity (MESH:D066126), metabolic dysfunction (MESH:D008659), sarcomas (MESH:D012509), germ cell tumors (MESH:D009373), necrosis (MESH:D009336), smallpox (MESH:D012899), lupus vulgaris (MESH:D008177), non-small-cell lung cancers (MESH:D002289), angiosarcoma (MESH:D006394), rickets (MESH:D012279), hypoxia (MESH:D000860), vomiting (MESH:D014839), solid (MESH:D018250)
- **Chemicals:** superoxide (MESH:D013481), 1PS (-), Cisplatin (MESH:D002945), Platinum (MESH:D010984), H2O2 (MESH:D006861), epirubicin (MESH:D015251), m-THPC (MESH:C072269), singlet oxygen (MESH:D026082), helium (MESH:D006371), motexafin lutetium (MESH:C102825), doxorubicin (MESH:D004317), Anthracycline (MESH:D018943), verteporfin (MESH:D000077362), molecular oxygen (MESH:D010100), carboplatin (MESH:D016190), pembrolizumab (MESH:C582435), Paclitaxel (MESH:D017239), heme (MESH:D006418), chlorine (MESH:D002713), amine (MESH:D000588), carbon (MESH:D002244), Cabazitaxel (MESH:C552428), vinca alkaloids (MESH:D014748), amino levulinate (MESH:D000622), indocyanine green (MESH:D007208), dATP (MESH:C026600), water (MESH:D014867), ATP (MESH:D000255), GSH (MESH:D005978), CO2 (MESH:D002245), lipid (MESH:D008055), Taxanes (MESH:D043823), purine (MESH:C030985), OH (MESH:C031356), atezolizumab (MESH:C000594389), gemcitabine (MESH:D000093542), Progesterone (MESH:D011374), alcohol (MESH:D000438), copper (MESH:D003300), Photofrin (MESH:D017323), hydrogen (MESH:D006859), taxane (MESH:C080625), camptothecin (MESH:D002166), Docetaxel (MESH:D000077143), NO (MESH:D009569), hydroxyl radicals (MESH:D017665), cAMP (MESH:D000242), argon (MESH:D001128), ROS (MESH:D017382), chloride (MESH:D002712)
- **Species:** Helicobacter pylori (species) [taxon 210], Human papillomavirus (species) [taxon 10566], Homo sapiens (human, species) [taxon 9606], Nicotiana tabacum (American tobacco, species) [taxon 4097]
- **Cell lines:** 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), MB-435 — Homo sapiens (Human), Amelanotic melanoma, Cancer cell line (CVCL_0417), MCF10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), IMR-90 — Homo sapiens (Human), Finite cell line (CVCL_0347), Chinese hamster — Cricetulus griseus (Chinese hamster), Spontaneously immortalized cell line (CVCL_0212), EMT-6 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_1923), MCF-7/DXR — Homo sapiens (Human), Ovarian endometrioid adenocarcinoma, Cancer cell line (CVCL_8744), CCL-226 — Mus musculus (Mouse), Undefined cell line type (CVCL_M023), HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), 3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), RIF-1 — Mus musculus (Mouse), Mouse fibrosarcoma, Cancer cell line (CVCL_H611), MCF-7 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_0031), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929285/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929285/full.md

## References

62 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929285/full.md

---
Source: https://tomesphere.com/paper/PMC12929285